Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • ESMO18

    - PMLiVE

    David Weinreich appointed as Merck’s Global Head of R&D and CMO, Healthcare

    Weinreich will be based in Billerica, Massachusetts at the company’s Research and Development site

    - PMLiVE

    MSD receives NICE recommendation for Keytruda in advanced endometrial cancer

    More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK

    - PMLiVE

    Merck’s perioperative Keytruda regimen approved by FDA for head and neck cancer

    More than 72,680 new cases of the disease are expected to be diagnosed in the US this year

    - PMLiVE

    Merck shares promising phase 3 results for Keytruda in ovarian cancer

    Approximately 20,890 cases of the disease are expected to be diagnosed in the US this year

    - PMLiVE

    Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

    Triple-negative breast cancer accounts for approximately 15% of all cases of the disease

    - PMLiVE

    Pfizer/Astellas share positive phase 3 results for Padcev in bladder cancer

    Approximately 614,000 people are diagnosed with bladder cancer globally every year

    - PMLiVE

    Merck shares positive phase 3 results for Keytruda/Lynparza regimen in ovarian cancer

    Ovarian cancer is the seventh most common cancer in women globally

    - PMLiVE

    Merck’s Keytruda recommended by NICE to reduce risk of lung cancer recurrence

    More than 5,000 patients in England are expected to be eligible for the anti-PD-1 therapy

    - PMLiVE

    Merck and Exelixis partner to evaluate new cancer combination treatments

    The companies will evaluate the regimens in head and neck cancer and renal cell carcinoma

    - PMLiVE

    Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval

    About 614,000 people are diagnosed with bladder cancer globally every year

    - PMLiVE

    Merck’s Keytruda shows promise as perioperative head and neck cancer treatment

    More than 58,450 new cases of the disease are expected to be diagnosed in the US this year

    - PMLiVE

    Merck’s Keytruda approved by FDA as first-line malignant pleural mesothelioma treatment

    More than 30,000 new cases of mesothelioma were diagnosed globally in 2022

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links